ArticleTherapeutic advances in gastroenterology2009
Second-line rescue therapy of helicobacter pylori infection.
Article in Therapeutic advances in gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Antibiotic Resistance ofMedicina (Kaunas, Lithuania) · 2022Article
- Cost-effectiveness of screening with polymerase chain reaction forJournal of gastrointestinal oncology · 2022Article
- Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2019Article
- Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment forThe American journal of tropical medicine and hygiene · 2017Article
- Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015Article
- Antibiotics resistance rate of Helicobacter pylori in Bhutan.World journal of gastroenterology · 2013Article
- Synthesis and biological evaluation of novel benzyl piperazine derivatives of 5-(5-nitroaryl)-1,3,4-thiadiazoles as Anti-Helicobacter pylori agents.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2013Article
- Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea.Gut and liver · 2013Article
- The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam.Journal of clinical gastroenterology · 2013Article
- Helicobacter pylori in First Nations and recent immigrant populations in Canada.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2012Review
- Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.Gastroenterology research and practice · 2012Article
- Sequential TherapyEuroasian journal of hepato-gastroenterologyArticle
- In vitro antagonistic activity of Lactobacillus casei against Helicobacter pylori.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori infection is the main known cause of gastritis, gastroduodenal ulcer disease and gastric cancer. After more than 20 years of experience in H. pylori treatment, however, the ideal regimen to treat this infection has still to be found. Nowadays, apart from having to know well first-line eradication regimens, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a 'rescue' treatment depends on which treatment is used initially. If a first-line clarithromycin-based regimen was used, a second-line metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin-based combination would be a third-line 'rescue' option. Alternatively, it has recently been suggested that levofloxacin-based 'rescue' therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, quadruple regimen may be reserved as a third-line 'rescue' option. Finally, rifabutin-based 'rescue' therapy constitutes an encouraging empirical fourth-line strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H. pylori eradication can finally be achieved in almost all patients if several 'rescue' therapies are consecutively given. Therefore, the attitude in H. pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.